Adapalene

Adapalene gel, 0.3% is indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. Adapalene gel, 0.3%, is a retinoid, indicated for the topical treatment of acne vulgaris in patients 12 years of age and older. ( 1 )

12.1 Mechanism of Action Adapalene binds to specific retinoic acid nuclear receptors but does not bind to cytosolic receptor protein. Biochemical and pharmacological profile studies have demonstrated that adapalene is a modulator of cellular differentiation, keratinization, and inflammatory processes. However, the significance of these findings with regard to the mechanism of action of adapalene for the treatment of acne is unknown. 12.2 Pharmacodynamics Clinical pharmacodynamic studies have not been conducted for adapalene gel.

Clinical clearance of Adapalene (Retinoid) relies on local esterase/enzymatic cleavage of adapalene with minimal hepatic cytochrome burden with a Trace plasma half-life; Adapalene acts primarily within superficial target tissue half-life; patients absorbing at < 5% transdermal or mucosal systemic uptake from Adapalene bioavailability typically observe target onset around initial local symptom modulation in 30–90 minutes; full tissue response over 1–3 weeks (adapalene).

FDA clinical labeling for Adapalene restricts administration in adapalene gel is contraindicated in patients who have known hypersensitivity to adapalene or any excipient of adapalene gel .; contraindicated in patients who have known hypersensitivity to adapalene or any excipient of adapalene gel. across 1 mg/g Gel, 1 mg/mL Swab, 1 mg/g Cream, 3 mg/g Gel, .1 g/100g Gel, with self-reported patient tracking dominated by nausea (8.5% of reports), headache (8.2% of reports), dizziness (5.6% of reports).